MiMedx Group is a placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. Co. is focused on wound care, surgical recovery applications, and musculoskeletal conditions. Co. derives its products from human placental tissues and process these tissues using its proprietary methods, including the PURION® process. Co. provides products primarily for use in the wound care, burn, and surgical recovery sectors of healthcare. Co. is a supplier of human placental allografts, which are human tissues that are derived from the donor and used to produce products that treat the recipient. The MDXG stock yearly return is shown above.
The yearly return on the MDXG stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MDXG annual return calculation with any dividends reinvested as applicable (on ex-dates).
|